The Fort Worth Press - Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

USD -
AED 3.672501
AFN 63.999821
ALL 82.253977
AMD 360.510128
ANG 1.790403
AOA 917.498737
ARS 1552.758602
AUD 1.483977
AWG 1.8025
AZN 1.699803
BAM 1.779545
BBD 2.01413
BDT 124.905034
BGN 1.77347
BHD 0.377331
BIF 3007.507166
BMD 1
BND 1.288858
BOB 11.66537
BRL 5.796998
BSD 1.000059
BTN 93.425596
BWP 13.998644
BYN 3.001178
BYR 19600
BZD 2.011401
CAD 1.429745
CDF 2317.999928
CHF 0.841035
CLF 0.02537
CLP 998.480068
CNY 6.66455
CNH 6.666355
COP 3314.81
CRC 445.481718
CUC 1
CUP 24.000873
CVE 100.328012
CZK 22.18105
DJF 178.098271
DKK 6.79992
DOP 60.559465
DZD 137.08899
EGP 53.689599
ERN 15
ETB 164.140883
EUR 0.90965
FJD 2.296797
FKP 0.758367
GBP 0.75805
GEL 2.595013
GGP 0.758367
GHS 11.73543
GIP 0.758367
GMD 73.502912
GNF 8860.460038
GTQ 7.643069
GYD 209.144677
HKD 7.846205
HNL 26.886001
HRK 6.831965
HTG 131.024035
HUF 333.008502
IDR 18270.5
ILS 3.24803
IMP 0.758367
INR 93.48355
IQD 1516.079284
IRR 1925253.999459
ISK 124.44977
JEP 0.758367
JMD 158.919789
JOD 0.708989
JPY 159.399503
KES 129.999947
KGS 87.449019
KHR 4080.072793
KMF 447.497235
KPW 900.00035
KRW 1336.402706
KWD 0.31172
KYD 0.833458
KZT 444.016797
LAK 22523.690592
LBP 89554.848894
LKR 332.782835
LRD 168.006442
LSL 16.919297
LTL 2.95274
LVL 0.60489
LYD 6.462884
MAD 9.981438
MDL 18.311519
MGA 4549.44565
MKD 56.069019
MMK 2099.8229
MNT 3605.49036
MOP 8.082545
MRU 40.524838
MUR 47.859893
MVR 15.409893
MWK 1734.212921
MXN 18.486875
MYR 4.094503
MZN 63.910141
NAD 16.918528
NGN 1349.369821
NIO 36.80602
NOK 9.625225
NPR 149.481136
NZD 1.81936
OMR 0.384508
PAB 1.000032
PEN 3.415635
PGK 4.499381
PHP 63.6585
PKR 276.505202
PLN 4.00316
PYG 6230.864068
QAR 3.64562
RON 4.865802
RSD 107.022012
RUB 82.04668
RWF 1480.116648
SAR 3.756442
SBD 8.098361
SCR 13.879028
SDG 601.49862
SEK 10.126925
SGD 1.288895
SHP 0.758581
SLE 23.050416
SLL 20969.503664
SOS 571.501363
SRD 37.43798
STD 20697.981008
STN 22.292284
SVC 8.750364
SYP 13002.000337
SZL 16.918877
THB 33.834502
TJS 9.216015
TMT 3.51
TND 3.026264
TOP 2.40776
TRY 50.417602
TTD 6.771395
TWD 32.941978
TZS 2650.003004
UAH 45.33545
UGX 4149.985442
UYU 40.627659
UZS 12019.053598
VES 914.603604
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 596.691317
XAG 0.02097
XAU 0.000259128447
XCD 2.70255
XCG 1.802383
XDR 0.707052
XOF 596.691317
XPF 108.509428
YER 236.503383
ZAR 16.94351
ZMK 9001.198726
ZMW 20.486504
ZWL 321.999592
SSP 5946.953244
MXV 2.073939
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of MVID and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of first IIT proof-of-concept results potentially in Q1 2025

Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan-Drug Designation by the FDA and the European Medicines Agency (EMA) for both MVID and SBS-IF

Text size:

The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of MVID and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of first IIT proof-of-concept results potentially in Q1 2025

Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan-Drug Designation by the FDA and the European Medicines Agency (EMA) for both MVID and SBS-IF

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that Napo's Phase 2 study to evaluate the efficacy of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for the indication of MVID in pediatric patients, has been initiated.

"The initiation of this double blind, placebo-controlled study in pediatric MVID patients is a key milestone for Jaguar," said Lisa Conte, Jaguar's founder, president, and CEO. "This study is one of five clinical efforts in rare diseases - three IIT proof-of-concept (POC) studies and two Phase 2 studies - for crofelemer for the orphan disease indications of MVID and/or SBS-IF in the United States, European Union, and/or Middle East/North Africa (MENA) regions. These studies are evaluating a novel oral powder for solution formulation of crofelemer - which is different from the FDA-approved oral formulation of crofelemer delayed-release tablets, Mytesi ® , available for people living with HIV/AIDS. Dosing of the first patient in each of these five studies is expected to occur during December 2024 and January 2025, with the availability of the first IIT POC result potentially in Q1 2025, with additional IIT POC results expected throughout 2025. In accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions in those countries."

The clinical protocol for the Phase 2 study in pediatric MVID patients has received regulatory clearances from the U.S. Food and Drug Administration (FDA) and the EMA, and the trial will be conducted at clinical sites in the US, Europe, and the MENA region.

"MVID and SBS-IF, rare and severe diseases requiring intensive parenteral nutrition (PN) and support, have severe morbidity and mortality implications as well as impacting the quality of life of both patients and their caregivers," Conte said. "In addition to the clinical endpoints, we plan to assess the quality-of-life impact on patients and caregivers as part of both the above-referenced Phase 2 studies."

MVID is an ultrarare pediatric disease, with an estimated prevalence of a couple of hundred patients globally. It is characterized by severe diarrhea and malabsorption, requiring intensive parenteral support for nutritional and fluid management. Each MVID patient is a unique patient; their journey requires very careful management of their nutritional needs, and there are currently no approved drug treatments for MVID.

"We expect that, if even just a very small number of patients show benefit with the extremely safe profile of crofelemer, this may potentially allow approval in the U.S. for crofelemer for MVID; support reimbursed early patient access to crofelemer for MVID in specific EU countries; and qualify crofelemer for participation in PRIME for MVID. PRIME is an EMA program providing enhanced interaction and early dialogue with developers of promising medicines that target an unmet medical need, with the goal of optimizing development plans and speeding up evaluation so the medicine can reach patients earlier," Conte said.

Crofelemer has been granted Orphan-Drug Designation by the FDA and the EMA for SBS-IF and MVID.

About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi ® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that dosing of the first patient in each of the five rare disease studies will occur during December 2024 and January 2025, Jaguar's expectation that the availability of the first IIT POC result may potentially occur in Q1 2025, Jaguar's expectation that additional IIT POC results may be available throughout 2025, Jaguar's expectation that, in accordance with the guidelines of specific EU countries, published data from clinical investigations could support early patient access to crofelemer for SBS-IF or MVID in these countries, Jaguar's expectation that it will assess the quality-of-life impact of SBS-IF and/or MVID on patients and caregivers as part of both Phase 2 studies of crofelemer, and Jaguar's expectation that, if even just a very small number of patients show benefit with crofelemer, this may allow approval in the U.S. for crofelemer for MVID, support reimbursed early patient access to crofelemer for MVID in specific EU countries, and qualify crofelemer for participation in PRIME for MVID. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

CONTACT:
[email protected]
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

P.Grant--TFWP